<mets:mets xmlns:mets="http://www.loc.gov/METS/" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.loc.gov/METS/ https://www.loc.gov/standards/mets/mets.xsd" OBJID="oai:wwu.de:511dbecf-6ff5-4e80-967d-a006ade6ca6a" LABEL="University of Muenster, Institutional Repository MIAMI"  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
          <mets:metsHdr CREATEDATE="2022-04-07T09:46:19">
            <mets:agent TYPE="OTHER" ROLE="OTHER" OTHERTYPE="SOFTWARE">
              <mets:name>Memory Alpha</mets:name>
            </mets:agent>
          </mets:metsHdr>
          <mets:dmdSec ID="DMD_511dbecf-6ff5-4e80-967d-a006ade6ca6a">
            <mets:mdWrap MIMETYPE="text/xml" MDTYPE="MODS">
              <mets:xmlData>
                <mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-7.xsd" version="3.7">
                  <mods:titleInfo type="uniform" lang="eng">
                    <mods:title script="Latn">Targeting of the autopenetrating bacterial effector protein YopM: a first approach</mods:title>
                  </mods:titleInfo>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/1195226276">
                    <mods:namePart type="given">Charlotte Stefanie Marie</mods:namePart>
                    <mods:namePart type="family">Bischof</mods:namePart>
                    <mods:namePart type="date">1991-</mods:namePart>
                    <mods:displayForm>Bischof, Charlotte Stefanie Marie</mods:displayForm>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">aut</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="personal" valueURI="http://d-nb.info/gnd/1102872350">
                    <mods:namePart type="given">M. Alexander</mods:namePart>
                    <mods:namePart type="family">Schmidt</mods:namePart>
                    <mods:displayForm>Schmidt, M. Alexander</mods:displayForm>
                    <mods:affiliation>FB 13: Biologie</mods:affiliation>
                    <mods:affiliation>FB 05: Medizinische Fakultät</mods:affiliation>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">ths</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>ULB Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Landesbibliothek Münster / Universitäts- und Landesbibliothek Münster</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:name type="corporate" valueURI="http://d-nb.info/gnd/5091030-9" altRepGroup="2">
                    <mods:namePart>Universität Münster / Universitäts- und Landesbibliothek</mods:namePart>
                    <mods:role>
                      <mods:roleTerm type="code" authority="marcrelator">own</mods:roleTerm>
                    </mods:role>
                  </mods:name>
                  <mods:genre>doctoralThesis</mods:genre>
                  <mods:genre authority="dct">Text</mods:genre>
                  <mods:originInfo>
                    <mods:dateIssued keyDate="yes">2019</mods:dateIssued>
                    <mods:dateOther>2019-08-26</mods:dateOther>
                    <mods:issuance>monographic</mods:issuance>
                  </mods:originInfo>
                  <mods:originInfo>
                    <mods:dateIssued encoding="w3cdtf">2019-09-20</mods:dateIssued>
                    <mods:dateModified encoding="w3cdtf">2019-09-20</mods:dateModified>
                    <mods:edition>[Electronic ed.]</mods:edition>
                  </mods:originInfo>
                  <mods:language>
                    <mods:languageTerm type="code" authority="iso639-2b">eng</mods:languageTerm>
                  </mods:language>
                  <mods:physicalDescription>
                    <mods:form>electronic</mods:form>
                    <mods:reformattingQuality>access</mods:reformattingQuality>
                    <mods:internetMediaType>application/pdf</mods:internetMediaType>
                    <mods:digitalOrigin>born digital</mods:digitalOrigin>
                  </mods:physicalDescription>
                  <mods:abstract lang="ger">Das autonom zellpenetrierende bakterielle Effektorprotein YopM hat die Eigenschaft, die Expression des proinflammatorischen Zytokins TNF-alpha, welches eine zentrale Rolle in der Pathogenese der rheumatoiden Arthritis spielt, zu reduzieren. Allerdings wirkt sich der Effekt des Proteins nicht selektiv auf bestimmte Zellen aus, sondern führte in allen bisher untersuchten Zelllinien zu einer reduzierten Zytokinexpression. Das Koppeln des Proteins an eine sogenannte „targeting“-Struktur könnte eine Möglichkeit bieten, den Ort des biologischen Effekts stärker einzugrenzen. Da aktiviertes Endothel im Rahmen der rheumatoiden Arthritis eine große Menge an E-Selektin exprimiert, wählten wir diesen Oberflächenmarker als Zielstruktur. Mit der vorliegenden Arbeit konnten wir zeigen, dass eine „targeting“-Modifikation von YopM keine negativen Auswirkungen auf die Proteininduktion und –purifikation, die Aufnahme in die Zelle oder den biologischen Effekt hat.</mods:abstract>
                  <mods:abstract lang="eng">The autopenetrating bacterial effector protein YopM is known to reduce the expression of the proinflammatory cytokine TNF-alpha which plays a central role in the pathogenesis of the autoimmune disease rheumatoid arthritis. YopM, though, does not exert this immunosuppressive effect selectively but reduces immune responses in all cell lines that were investigated so far. Adding a targeting structure to YopM might be a possible approach to achieve a more selective and localized effect. Since the activated endothelium in rheumatoid arthritis expresses a high amount of E-selectin we used this surface marker as the target structure. With this study, we were able to show that a targeting modification of YopM does not impair induction and purification of the protein, cellular uptake and reduction of TNF-alpha expression.</mods:abstract>
                  <mods:tableOfContents lang="eng">1 Introduction ..................................................................................................................................... 1&#13;
1.1 How the human organism ensures its own survival ....................................................................... 1&#13;
1.2 The human immune system ........................................................................................................... 1&#13;
1.3 Autoimmune disease ...................................................................................................................... 4&#13;
1.4 Rheumatoid arthritis ...................................................................................................................... 5&#13;
1.5 Current treatment options of autoimmune diseases ..................................................................... 6&#13;
1.6 Targeting of therapeutic agents- an approach to achieve site-specific effects .............................. 8&#13;
1.7 Manipulation of the immune system by pathogenic Yersinia ........................................................ 9&#13;
1.8 The drugs from bugs concept: the effector protein YopM as a possible therapeutic agent ........ 11&#13;
1.9 Aims of this study ......................................................................................................................... 12&#13;
2 Materials ........................................................................................................................................ 13&#13;
2.1 Bacterial strains ............................................................................................................................ 13&#13;
2.2 Media and supplements for bacterial growth .............................................................................. 13&#13;
2.3 Eukaryotic cell lines ...................................................................................................................... 13&#13;
2.4 Media and supplements for eukaryotic cell cultures ................................................................... 14&#13;
2.5 Cell culture supplies ..................................................................................................................... 15&#13;
2.6 Enzymes and enzyme buffers ....................................................................................................... 15&#13;
2.7 Plasmids ........................................................................................................................................ 16&#13;
2.8 Oligonucleotides ........................................................................................................................... 17&#13;
2.9 Antibodies and fluorescent dyes .................................................................................................. 18&#13;
2.10 Kits ................................................................................................................................................ 19&#13;
2.11 Buffers and solutions .................................................................................................................... 20&#13;
2.12 DNA and protein size marker ....................................................................................................... 21&#13;
2.13 Chemicals ..................................................................................................................................... 21&#13;
2.14 Laboratory consumable supplies .................................................................................................. 23&#13;
2.15 Laboratory equipment ................................................................................................................. 24&#13;
2.16 Software ....................................................................................................................................... 25&#13;
3 Methods ......................................................................................................................................... 26&#13;
3.1 Microbiological methods .............................................................................................................. 26&#13;
3.1.1 Cultivation and strain maintenance of bacteria ..................................................................... 26&#13;
3.1.2 Measurement of optical density ............................................................................................. 26&#13;
3.2 Cytological methods ..................................................................................................................... 26&#13;
3.2.1 Thawing of cryoconserved cells .............................................................................................. 26&#13;
3.2.2 Cultivation of eukaryotic cells ................................................................................................. 27&#13;
3.2.3 Strain maintenance of eukaryotic cells ................................................................................... 27&#13;
3.2.4 Incubation of eukaryotic cells with recombinant protein ...................................................... 27&#13;
3.3 Molecular biological methods ...................................................................................................... 28&#13;
3.3.1 Plasmid mini preparation ....................................................................................................... 28&#13;
3.3.2 Polymerase chain reaction (PCR) ............................................................................................ 28&#13;
3.3.3 Separation of DNA fragments by agarose gel electrophoresis ............................................... 30&#13;
3.3.4 DNA purification after PCR or enzyme digest and DNA extraction from agarose gels .......... 32&#13;
3.3.5 Photometric DNA quantification ............................................................................................ 32&#13;
3.3.6 Restriction of DNA .................................................................................................................. 33&#13;
3.3.7 Ligation of DNA fragments...................................................................................................... 33&#13;
3.3.8 Transformation of bacteria ..................................................................................................... 34&#13;
3.3.8.1 Preparation of electrocompetent E. coli .................................................................................... 34&#13;
3.3.8.2 Transformation by electroporation ........................................................................................... 34&#13;
3.3.9 DNA Sequencing ..................................................................................................................... 35&#13;
3.3.10 Analysis of eukaryotic gene expression .................................................................................. 35&#13;
3.3.10.1 Isolation of RNA ......................................................................................................................... 35&#13;
3.3.10.2 Synthesis of cDNA ...................................................................................................................... 36&#13;
3.3.10.3 Quantitative real time PCR (qPCR) ............................................................................................. 36&#13;
3.3.10.4 Relative quantification with 2-ΔΔC&#13;
T method ................................................................................ 38&#13;
3.4 Protein biochemical methods ...................................................................................................... 38&#13;
3.4.1 Expression and purification of recombinant proteins ............................................................ 38&#13;
3.4.1.1 Expression of recombinant proteins .......................................................................................... 38&#13;
3.4.1.2 Preparation of bacterial cell lysate ............................................................................................ 39&#13;
3.4.1.3 Purification of recombinant proteins by affinity chromatography ............................................ 39&#13;
3.4.1.4 Protein dialysis and concentration ............................................................................................ 40&#13;
3.4.2 Quantification of protein concentration ................................................................................ 40&#13;
3.4.3 Protein labeling with fluorescent dyes ................................................................................... 41&#13;
3.4.4 Discontinuous SDS polyacrylamide gel electrophoresis ......................................................... 42&#13;
3.4.5 Staining of proteins in polyacrylamide gels ............................................................................ 43&#13;
3.4.6 Western blotting by tank blotting .......................................................................................... 44&#13;
3.4.7 Immunologic detection of proteins after Western blotting ................................................... 44&#13;
3.4.8 Cellular fractionation .............................................................................................................. 45&#13;
3.4.9 Immunofluorescence microscopy........................................................................................... 46&#13;
3.4.10 Flow cytometry ....................................................................................................................... 47&#13;
3.5 Statistical analysis ......................................................................................................................... 48&#13;
4 Results ............................................................................................................................................ 50&#13;
4.1 Cloning and purification of TSES-YopM ........................................................................................ 50&#13;
4.2 Comparison of cellular uptake of YopM and TSES-YopM ............................................................. 55&#13;
4.2.1 Analysis of intracellular localization of TSES-YopM by fluorescence microscopy ................. 58&#13;
4.2.2 Analysis of protein uptake of TSES-YopM by flow cytometry ................................................ 61&#13;
4.3 Colocalization analysis of TSES-YopM and its target marker........................................................ 65&#13;
4.4 Functionality of TSES-YopM ......................................................................................................... 68&#13;
5 Discussion ...................................................................................................................................... 71&#13;
5.1 Impact of the modification on the protein purification ............................................................... 73&#13;
5.2 Impact of the modification on cellular uptake ............................................................................. 74&#13;
5.3 Impact of the modification on functionality ................................................................................ 78&#13;
5.4 Effect of the targeting structure TSES on protein distribution intra-cellularly and on the cell&#13;
surface .......................................................................................................................................... 79&#13;
5.5 Outlook ......................................................................................................................................... 80&#13;
6 References ..................................................................................................................................... 84&#13;
7 Annex ................................................................................................................................................ I&#13;
List of figures ........................................................................................................................................ IV&#13;
List of tables .......................................................................................................................................... V&#13;
List of abbreviations ............................................................................................................................. VI&#13;
Curriculum vitae .................................................................................................................................... X</mods:tableOfContents>
                  <mods:targetAudience>specialized</mods:targetAudience>
                  <mods:subject>
                    <mods:topic lang="ger">YopM; E-Selektin; Immunsuppression; targeted therapy; aktiviertes Endothel</mods:topic>
                  </mods:subject>
                  <mods:subject>
                    <mods:topic lang="eng">YopM, targeting, E-selectin, immunosuppression, targeted therapy, activated endothelium</mods:topic>
                  </mods:subject>
                  <mods:classification authority="ddc">610</mods:classification>
                  <mods:identifier type="urn">urn:nbn:de:hbz:6-13179727926</mods:identifier>
                  <mods:location>
                    <mods:url access="object in context">https://miami.uni-muenster.de/Record/511dbecf-6ff5-4e80-967d-a006ade6ca6a</mods:url>
                  </mods:location>
                  <mods:accessCondition type="use and reproduction">
                    <mods:extension>
                      <ma:maWrap xmlns:ma="http://memoryalpha.ulb.uni-muenster.de">
                        <ma:licence>
                          <ma:displayLabel>CC BY 4.0</ma:displayLabel>
                          <ma:targetUrl>http://creativecommons.org/licenses/by/4.0/</ma:targetUrl>
                        </ma:licence>
                      </ma:maWrap>
                    </mods:extension>
                  </mods:accessCondition>
                  <mods:recordInfo>
                    <mods:recordIdentifier>oai:wwu.de:511dbecf-6ff5-4e80-967d-a006ade6ca6a</mods:recordIdentifier>
                  </mods:recordInfo>
                </mods:mods>
              </mets:xmlData>
            </mets:mdWrap>
          </mets:dmdSec>
          <mets:amdSec ID="AMD_511dbecf-6ff5-4e80-967d-a006ade6ca6a">
            <mets:rightsMD ID="RIGHTSMD_511dbecf-6ff5-4e80-967d-a006ade6ca6a">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVRIGHTS">
                <mets:xmlData>
                  <dv:rights xmlns:dv="http://dfg-viewer.de/">
                    <dv:owner>Universitäts- und Landesbibliothek Münster</dv:owner>
                  </dv:rights>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:rightsMD>
            <mets:digiprovMD ID="DIGIPROVMD_511dbecf-6ff5-4e80-967d-a006ade6ca6a">
              <mets:mdWrap MDTYPE="OTHER" MIMETYPE="text/xml" OTHERMDTYPE="DVLINKS">
                <mets:xmlData>
                  <dv:links xmlns:dv="http://dfg-viewer.de/">
                    <dv:reference>https://miami.uni-muenster.de/Record/511dbecf-6ff5-4e80-967d-a006ade6ca6a</dv:reference>
                    <dv:presentation/>
                  </dv:links>
                </mets:xmlData>
              </mets:mdWrap>
            </mets:digiprovMD>
          </mets:amdSec>
          <mets:fileSec>
            <mets:fileGrp USE="DEFAULT">
              <mets:file MIMETYPE="application/pdf" CHECKSUM="bda3c999e55e66636f03e28cf8b53e8a90310e5459cfe494f9bb7425973ce1ec" CREATED="2019-09-20T07:33:27" CHECKSUMTYPE="SHA-256" SIZE="4096166" ID="ID_FIL_diss_bischof.pdf_DEFAULT">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/document/miami/511dbecf-6ff5-4e80-967d-a006ade6ca6a/diss_bischof.pdf" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
            <mets:fileGrp USE="DOWNLOAD">
              <mets:file MIMETYPE="application/pdf" ID="DOW511dbecf-6ff5-4e80-967d-a006ade6ca6a">
                <mets:FLocat xlink:href="https://repositorium.uni-muenster.de/transfer/miami/511dbecf-6ff5-4e80-967d-a006ade6ca6a" LOCTYPE="URL"/>
              </mets:file>
            </mets:fileGrp>
          </mets:fileSec>
          <mets:structMap TYPE="PHYSICAL">
            <mets:div ID="ID_PHY_511dbecf-6ff5-4e80-967d-a006ade6ca6a" TYPE="physSequence">
              <mets:div ID="ID_PHY_diss_bischof.pdf">
                <mets:fptr FILEID="ID_FIL_diss_bischof.pdf_DEFAULT"/>
              </mets:div>
            </mets:div>
          </mets:structMap>
          <mets:structMap TYPE="LOGICAL">
            <mets:div ADMID="AMD_511dbecf-6ff5-4e80-967d-a006ade6ca6a" DMDID="DMD_511dbecf-6ff5-4e80-967d-a006ade6ca6a" ID="ID_LOG_511dbecf-6ff5-4e80-967d-a006ade6ca6a" TYPE="Monograph">
              <mets:div ID="ID_LOG_ID_PHY_diss_bischof.pdf"/>
            </mets:div>
          </mets:structMap>
          <mets:structLink>
            <mets:smLink xlink:from="ID_LOG_511dbecf-6ff5-4e80-967d-a006ade6ca6a" xlink:to="ID_PHY_511dbecf-6ff5-4e80-967d-a006ade6ca6a"/>
            <mets:smLink xlink:from="ID_LOG_ID_PHY_diss_bischof.pdf" xlink:to="ID_PHY_diss_bischof.pdf"/>
          </mets:structLink>
        </mets:mets>